Rampart IC, a Birmingham-based medical technology company, announced the successful close of its $21.6 million Series B funding round led by Vensana Capital. The investment will accelerate Rampart’s global commercialization, product development, and clinical expansion into new service lines. Rampart’s radiation protection systems—designed to eliminate the need for lead aprons—offer full-body shielding for interventional teams, addressing both radiation exposure and the orthopedic injuries commonly caused by traditional protective gear.

The partnership with Vensana Capital marks a significant milestone for Rampart, reinforcing the growing clinical demand for safer, more advanced shielding solutions. Backed by strong peer-reviewed research, Rampart is reshaping safety standards in cath labs and interventional suites, where a recent SCAI survey highlighted the toll of outdated protection methods: over 60% of interventional workers report orthopedic injuries, and nearly 1 in 5 limit lab time due to radiation concerns. With this new funding, Rampart is positioned to expand its impact and drive a lead-free future for healthcare professionals.